

July 22, 2013



ResMed Takes New Action to Enforce Patents

New ITC Investigation Filed against BMC and 3B for Patent Infringement on Devices and Masks

SAN DIEGO, July 22, 2013 /PRNewswire/ -- ResMed (NYSE: RMD), an innovator and pioneer in developing products for the treatment of sleep-disordered breathing and respiratory conditions, has filed a new legal action in the International Trade Commission (ITC) and an amended complaint in U.S. federal court to stop the infringement of ResMed patents.

(Logo: <https://photos.prnewswire.com/prnh/20100203/RESMEDLOGO>)

ResMed filed the action against Chinese medical device manufacturer BMC Medical Co., Ltd. (BMC) and its U.S. sales subsidiary, 3B Products, LLC, (3B) asserting patent infringement by:

- The RESmart CPAP and RESmart Auto CPAP devices
- The Willow nasal pillows patient interface and the iVolve nasal mask.

ResMed is asking the ITC to stop the importation and sales of these products in the United States. ResMed has also amended a pending action in the U.S. federal court to assert additional patents that BMC and 3B are infringing. ResMed is asking the court to stop the infringement and to award damages against BMC and 3B.

"ResMed built its market leadership by investing in superior technology for sleep-disordered breathing therapy," said ResMed global general counsel and chief administrative officer David Pendarvis. "The proprietary technology in our masks and flow generators makes them comfortable and user-friendly, and our data management and reporting tools create a faster, smoother path to patient engagement. We will continue to defend our proprietary technology by enforcing our patents against those who unfairly copy our products."

About ResMed:

ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

Contacts:

For News Media

Gretchen Griswold

Director, Global Corporate Communications

O: 858-836-6789

news@resmed.com

For the Investor Community

Constance Bienfait

Director, Investor Relations

O: 858-836-5971

constance.bienfait@resmed.com

SOURCE ResMed Inc.